Cardiorenal evidence review: CKD progression and cardiovascular outcomes
Nonsteroidal mineralocorticoid receptor antagonist · Evidence Stability Review
CKD associated with Type 2 Diabetes
No material change shown for current intended use, subject to existing caveats.
Sourced from FDA labels, pivotal trial publications, and two major guideline bodies. Two phase 3 trials (n=13,026 pooled) with consistent kidney and cardiovascular composite outcomes. Guideline recommendations strengthened from suggested to recommended (Level A) over the observation window.
Research use: test whether the source state, cutoff, and subsequent transition can be reconstructed without temporal leakage.
Source timeline
- 2020-10 FIDELIO-DKD primary results published
- 2022-08 FDA label expansion to include CV indication
- 2024-05 KDIGO guidance elevated recommendation to Level A · Illustrative
Metabolic evidence example (T1D)
Anti-CD3 monoclonal antibody · Regulatory Review
Type 1 Diabetes
Observable movement within the stated review window; no conclusion is implied.
Historical example of evidence movement preceding formal regulatory recognition.
Research use: test whether the source state, cutoff, and subsequent transition can be reconstructed without temporal leakage.
Source timeline
- 2022-11 First phase 3 readout in T1D population
- 2023-07 Advisory committee discussion
- 2024-02 Label expansion in comparator jurisdiction
Sample Review Package: Restriction Review for Amyloid-Directed Therapy in Early Alzheimer's Disease
Amyloid-directed therapy · Coverage Review
Early Alzheimer's Disease
Evidence-supported scope has changed relative to stated use; a qualified reviewer should take another look.
A broad coverage topic narrowed to one testable disputed claim, a one-page committee baseline, and a source-bound audit appendix. Public-domain concepts only.
Research use: test whether the source state, cutoff, and subsequent transition can be reconstructed without temporal leakage.
Source timeline
- 2021-06 Accelerated approval based on surrogate endpoint
- 2023-01 CMS National Coverage Determination issued
- 2024-07 Confirmatory trial CDR-SB results published
Neurodegenerative review (Alzheimer's)
Anti-amyloid monoclonal antibody · Safety Review
Alzheimer's Disease
Observable movement within the stated review window; no conclusion is implied.
Historical example separating source-supported safety questions from public speculation.
Research use: test whether the source state, cutoff, and subsequent transition can be reconstructed without temporal leakage.
Source timeline
- 2023-01 Safety signal surfaced in post-market registry
- 2023-09 Regulatory request for enhanced safety review · Illustrative
- 2024-12 Updated adverse-event meta-analysis · Illustrative
Semaglutide (illustrative example): from high-risk comorbidity settings to general obesity weight management
GLP-1 receptor agonist · Population Drift Review
Type 2 Diabetes / Obesity
Evidence-supported scope has changed relative to stated use; a qualified reviewer should take another look.
The same molecule is now being promoted in a broader population than the pivotal trials primarily studied. The move from high-risk diabetic or cardiovascular settings to general weight-management settings changes the strength of the supporting evidence and the review action.
Research use: test whether the source state, cutoff, and subsequent transition can be reconstructed without temporal leakage.
Source timeline
- 2017-12 Initial FDA approval for Type 2 Diabetes
- 2021-06 FDA approval for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity
- 2024-03 SELECT trial cardiovascular outcomes published · Illustrative
- 2025-01 CMS coverage determination for obesity indication issued · Illustrative
GLP-1 receptor agonist claim history: diabetes to obesity indication
GLP-1 receptor agonist · Provenance Review
Type 2 Diabetes / Obesity
Observable movement within the stated review window; no conclusion is implied.
Reconstructed from 22 public encyclopedia revisions. Three claim families emerged: diabetes/family-history indication, obesity/weight-management indication, and a disputed pathway.
Research use: test whether the source state, cutoff, and subsequent transition can be reconstructed without temporal leakage.
Source timeline
- 2009-01 Article created around GLP-1 agonists for type 2 diabetes
- 2010-01 Dose and family-history details added
- 2021-08 Obesity and weight-management claim drift appears
- 2023-11 Disputed pathway surfaced by reverting edit pattern
Liraglutide claim history: single-drug provenance reconstruction
Liraglutide · Provenance Review
Type 2 Diabetes / Obesity
Observable movement within the stated review window; no conclusion is implied.
Reconstructed from 20 public encyclopedia revisions. Twenty-two stable claim families emerged; two-analyst reproducibility validation is pending.
Research use: test whether the source state, cutoff, and subsequent transition can be reconstructed without temporal leakage.
Source timeline
- 2010-01 Liraglutide mentioned as under investigation in broader GLP-1 article
- 2010-01 Approval status and dosing details added
- 2012-01 Article structure stabilizes around approved indications